Trial for Treatment Refractory Trigeminal Neuralgia
Trial ID or NCT#
NCT03941834
Status
NOT RECRUITING
Purpose
The purpose of this study is to evaluate the efficacy of BHV3000 compared to placebo for subjects with treatment refractory Trigeminal Neuralgia as measured by a 2-point or greater reduction in the average Numeric Pain Rating Scale between the two-week treatment phases.
Official Title
BHV3000-202: Phase 2: A Double-Blind, Placebo Controlled, Crossover Trial of BHV-3000 (Rimegepant) for Treatment Refractory Trigeminal Neuralgia
Investigator(s)
Meredith Barad, MD
Pain management specialist,
Headache and facial pain specialist
Clinical Associate Professor, Anesthesiology, Perioperative and Pain Medicine
Clinical Associate Professor (By courtesy), Adult Neurology
Contact us to find out if this trial is right for you.
Contact
Anthony Bet
650-683-5823
View on ClinicalTrials.gov
